We assign a fundamental rating of 7 out of 10 to GMAB. GMAB was compared to 524 industry peers in the Biotechnology industry. GMAB gets an excellent profitability rating and is at the same time showing great financial health properties. GMAB is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make GMAB a good candidate for growth and quality investing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 12.18 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.52 | ||
| Fwd PE | 18.74 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.33 | ||
| EV/EBITDA | 11.13 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
31.9
-1.13 (-3.42%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.52 | ||
| Fwd PE | 18.74 | ||
| P/S | 5.48 | ||
| P/FCF | 16.33 | ||
| P/OCF | 15.42 | ||
| P/B | 3.42 | ||
| P/tB | 5.39 | ||
| EV/EBITDA | 11.13 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 12.18 |
ChartMill assigns a fundamental rating of 7 / 10 to GMAB.
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 13.52 and the Price/Book (PB) ratio is 3.42.
The financial health rating of GENMAB A/S -SP ADR (GMAB) is 8 / 10.